McKesson Corporation

Consolidated revenues grew every fiscal year from FY2016 ($190.9B) through FY2025 ($359.1B), including through the COVID-driven 2020 recession, reflecting non-discretionary prescription demand and multi-year distribution contracts with major retail and hospital customers. Revenue is volume-driven rather than subscription-based, but high operational switching costs for large customers provide durable forward visibility.

The U.S. Pharmaceutical segment accounted for 91.3% of consolidated revenues in FY2025 ($327.7B of $359.1B total); the three remaining segments (RxTS, Medical-Surgical, International) collectively represent less than 9%. The announced separation of Medical-Surgical Solutions will concentrate the portfolio further on pharmaceutical distribution and services.

Approximately 95.9% of FY2025 revenues originated in the United States; the International segment (Canada and Norway) contributed $14.7B, or roughly 4.1% of consolidated revenues. The U.S. healthcare regulatory and reimbursement framework is the dominant operating environment with negligible revenue exposure to other geographies.

Core pharmaceutical distribution has limited operating leverage, as logistics, DEA compliance, and cold-chain infrastructure scale roughly proportionally with volume. The RxTS and specialty oncology services components carry more software-like unit economics and contribute modestly better margins than the base distribution business, but these represent a small fraction of total revenues.

Pharmaceutical distribution revenue is transactional by structure but functionally non-discretionary, as patients and health systems cannot defer most prescription drug purchases; consolidated revenues have been resilient through every major economic contraction since FY2016. The specialty, oncology, and biopharma services components carry multi-year service relationships and mission-critical workflows, though they remain a modest share of consolidated revenues.